JP2007297344A - Raw preparation for ameliorating pollinosis - Google Patents
Raw preparation for ameliorating pollinosis Download PDFInfo
- Publication number
- JP2007297344A JP2007297344A JP2006127542A JP2006127542A JP2007297344A JP 2007297344 A JP2007297344 A JP 2007297344A JP 2006127542 A JP2006127542 A JP 2006127542A JP 2006127542 A JP2006127542 A JP 2006127542A JP 2007297344 A JP2007297344 A JP 2007297344A
- Authority
- JP
- Japan
- Prior art keywords
- hay fever
- product
- lactic acid
- pollinosis
- koji
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
Description
本発明は、花粉症改善用素剤に係り、特に穀類を原料とした生成物を利用して得られる花粉症改善用素剤に関する。 The present invention relates to a hay fever remedy, and more particularly to a hay fever remedy obtained using a product made from cereals.
本発明において、穀類とは、大豆、米、麦、とうもろこしやこれらの粕等を意味し、本発明はこれらの穀類の少なくとも１種を原料基質として使用する。 In the present invention, cereal means soybeans, rice, wheat, corn, potatoes and the like, and the present invention uses at least one of these cereals as a raw material substrate.
本出願人は、すでに穀物由来の生成物について、その製造方法を特許第２６９６０５７号公報において提案している。この製造方法によれば、穀類を原料として麹菌によって製麹させて蛋白質を分解し、その後に加水分解することによって得られた生成物においては、穀類の状態を固形状にしたままで穀類中のフィチン酸が除去され、生成物中に含有されているビタミンＢ類等の活性が高く維持され、生成物中に含有されているミネラルの吸収も容易とされ、更にその吸収も促進可能とされている。このような穀類由来の生成物は人の健康によく作用するものである。 The present applicant has already proposed a method for producing a grain-derived product in Japanese Patent No. 2696057. According to this production method, in a product obtained by producing a cereal using koji mold as a raw material, decomposing protein, and then hydrolyzing it, the cereal state remains solid while the cereal is in a solid state. Phytic acid is removed, the activity of vitamin B and the like contained in the product is maintained high, the absorption of minerals contained in the product is facilitated, and the absorption can also be promoted. Yes. Such cereal-derived products work well for human health.
また、本出願人は、すでに穀類の１種である大豆由来のイソフラボンアグリコンについて、その製造方法を特許第３０１４１４５号公報において、豆類を原料として麹菌によって発酵させて蛋白質を分解し、その後に加水分解することによって得られた生成物には大豆イソフラボングリコシドが麹菌の酵素（β−グリコシダーゼ）でイソフラボンアグリコンに変化されるため、イソフラボンアグリコンがリッチに含有されており、この生成物が人間や哺乳類に対して薬効等の生体活性を促進する作用をなすことを提案している。 In addition, the applicant of the present invention disclosed a method for producing isoflavone aglycone derived from soybean, which is a kind of cereal, in Japanese Patent No. 3014145, using bean as a raw material to ferment by a koji mold, followed by hydrolysis, followed by hydrolysis. The soy isoflavone glycoside is converted into an isoflavone aglycone by a koji mold enzyme (β-glycosidase) in the product obtained by this, so that the isoflavone aglycone is richly contained. It has been proposed to promote biological activities such as medicinal effects.
昨年（２００５年）の春期における花粉症の症状は一昨年より遙かに重いものであった。これは図２に示すように昨年の春期に飛来した花粉量が一昨年の５０〜１００倍にも達したことによる。 The symptoms of hay fever last spring (2005) were much more severe than last year. This is because the amount of pollen flying in the spring last year reached 50 to 100 times that of the previous year as shown in FIG.
このように大きく問題視される花粉症を改善することのできる効果を発揮できるものが望まれている。 Thus, what can exhibit the effect which can improve the pollinosis regarded as a big problem is desired.
本発明はこれらの点に鑑みてなされたものであり、人間における花粉症の改善に有効な作用を備えた穀類由来の花粉症改善用素剤を提供することを目的とする。 The present invention has been made in view of these points, and an object of the present invention is to provide a cereal-derived hay fever remedy that has an effective action for improving hay fever in humans.
本発明者は鋭意研究し、本出願人が特許第２６９６０５７号および特許第３０１４１４５号において既に提案している生成物について、その成分と作用とを究明し、乳酸菌を含有している生成物を花粉症を患っている被検者に投与したところ、花粉症が回復されたことを確認して本発明を完成させたものである。 The present inventor has intensively studied, studied the components and actions of the products already proposed by the present applicant in Patent No. 2696057 and Patent No. 3014145, and the product containing lactic acid bacteria is pollen. The present invention was completed by confirming that hay fever was recovered when administered to a subject suffering from symptom.
このようにしてなされた本発明の花粉症改善用素剤は、穀類に麹菌を接種して製麹し、この製麹処理による生成物に加水することにより当該生成物中の組成要素を加水分解した固体組成物であって、乳酸菌を含有するとともに花粉症を改善することができる固体組成物であることを特徴とする。 The base for hay fever improvement of the present invention thus made is inoculated with gonococcal cereals to make koji, and then hydrolyzed into the product by this koji making process, thereby hydrolyzing the compositional elements in the product. A solid composition comprising a lactic acid bacterium and capable of improving hay fever.
また、本発明の花粉症改善用素剤は、前記乳酸菌がペディオコッカス属とエントロコッカス属とを含み、当該ペディオコッカス属およびエントロコッカス属の菌数の比が約３：１であることを特徴とする。 In the pollen allergy improvement agent of the present invention, the lactic acid bacterium includes a genus Pediococcus and an Entrococcus genus, and the ratio of the number of the genus Pediococcus and Entrococcus is about 3: 1. It is characterized by.
また、本発明の花粉症改善用素剤は、前記固体生成物が前記生成物に対する麹菌および乳酸菌による代謝物を含むことを特徴とする。 In the pollen allergy improvement agent of the present invention, the solid product contains a metabolite by gonococci and lactic acid bacteria with respect to the product.
このようにして形成されている本発明の花粉症改善用素剤は、人間の花粉症の改善に有効な作用を発揮するので、種々の原因によって発生する花粉症突の治療に用いることができる。 The base for improving hay fever of the present invention thus formed exhibits an effective action for improving human hay fever, and thus can be used for treatment of hay fever caused by various causes. .
本発明の花粉症改善用素剤によれば、穀類由来の固形生成物であって人間における花粉症の改善に有効であるという優れた効果を奏する。 According to the base for improving hay fever of the present invention, it is a solid product derived from cereals and has an excellent effect of being effective in improving hay fever in humans.
以下、図１を用いて本発明の花粉症改善用素剤の実施形態について説明する。 Hereinafter, an embodiment of the hay fever improving ingredient of the present invention will be described with reference to FIG.
本実施形態においては、本出願人が特許第２６９６０５７号および特許第３０１４１４５号において既に提案している生成物であって、「原料となる穀類の１種である大豆等の豆類に対して麹菌を用いて製麹処理を施すとともにその生成物に対して加水分解処理を施して、蛋白質が分解されており、イソフラボンアグリコンを多量に含有する生成物やフイチン酸が完全に分解除去された固体組成物において、乳酸菌を含有するとともに花粉症を改善することができる固体組成物」を発明品とする。 In the present embodiment, the product already proposed by the present applicant in Patent No. 2696057 and Patent No. 3014145, which is “a koji mold against beans such as soybeans, which is one kind of raw cereals” A solid composition in which the product is hydrolyzed, the protein is decomposed, the product containing a large amount of isoflavone aglycone, and the phytic acid is completely decomposed and removed. In the present invention, the “solid composition that contains lactic acid bacteria and can improve hay fever” is an invention.
図１は前記特許第２６９６０５７号および特許第３０１４１４５号において提案している生成物であって、豆類の１種である大豆粕のイソフラボン化合物の配糖体を分解して、アグリコンを多量に含むイソフラボン化合物を生成した生成物の製造方法の１実施形態および同時に大豆粕中のフィチン酸を除去した生成物の製造方法の１実施形態を示す工程図である。 FIG. 1 is a product proposed in Patent Nos. 2696057 and 3014145, which is an isoflavone containing a large amount of aglycone by decomposing a glycoside of an isoflavone compound of soybean meal which is a kind of beans. It is process drawing which shows one Embodiment of the manufacturing method of the product which produced | generated the compound, and 1 embodiment of the manufacturing method of the product which removed the phytic acid in soybean meal simultaneously.
図１の工程に沿って説明すると、先ず脱脂大豆を蒸煮する。この蒸煮を施すことにより、麹菌の増殖が容易となる。また、この脱脂大豆の蒸煮は製造目的等に応じてバッチ式や連続式で行うと良い。 If it demonstrates along the process of FIG. 1, first, defatted soybean will be cooked. By performing this cooking, the growth of koji molds is facilitated. The defatted soybeans may be cooked batchwise or continuously depending on the purpose of manufacture.
そして、この蒸煮が終了した脱脂大豆を一旦冷却して、脱脂大豆中の水分量を麹菌が増殖可能な量（例えば、３７重量％）とさせる。 Then, the defatted soybean that has been cooked is once cooled, and the amount of water in the defatted soybean is adjusted to an amount that allows the koji mold to grow (for example, 37% by weight).
このようにして水分量を整えられた脱脂大豆に対して、本発明方法が以下のようにして行なわれる。 Thus, the method of this invention is performed as follows with respect to the defatted soybean in which the moisture content was adjusted.
即ち、蒸煮が終了した脱脂大豆を殺菌し、冷却した後、脱脂大豆と麹菌との配合割合を、例えば脱脂大豆を４００ｋｇに対して麹菌胞子を８×１０7 個／ｇに調整した種麹（精白米にて調整）を２００ｇを混合した。更に、製麹のスタート時には３２℃に冷却した後、品温が４０℃になるまで通風しないで４０℃になった時点で通風しながら、温度上昇を抑えた。スタートから約１７時間後の最初の撹拌（盛工程）を行った。脱脂大豆の熱を冷まし、撹拌後品温が３５℃前後になるように通風しながら、温度をコントロールをした。次いで約８時間後に２回目の撹拌（仲工程）を行い、熱を冷ました。再び品温を通風で３５℃前後にコントロールし、更に約１６時間後に３回目の撹拌（仕舞工程）を前回同様に行った。その後は品温が約３８℃になるように通風しながら、温度コントロールし、スタートから４８時間後に製麹を終了させた。製麹終了後、水分含量が５０％になるように撹拌しながら、水分調整を行い、品温が約５０℃になるように加温後、４８時間以上麹菌の酵素で脱脂大豆中のイソフラボン化合物の大部分がアグリコン体になるまで加水分解した。表１に示す通り本発明による処理により脱脂大豆のイソフラボン化合物はアグリコン体のダイゼインが主体となるように多量に得られた。 That is, after defatted soybeans that have been cooked are sterilized and cooled, the blending ratio of defatted soybeans and koji molds, for example, 400 kg of defatted soybeans, and koji molds adjusted to 8 × 10 7 spores / g 200 g of the mixture was adjusted with polished rice. In addition, after the start of the iron making, after cooling to 32 ° C., the temperature rise was suppressed while ventilating when the temperature reached 40 ° C. until the product temperature reached 40 ° C. About 17 hours after the start, the first stirring (pick-up process) was performed. The heat of the defatted soybean was cooled, and the temperature was controlled while ventilating so that the product temperature was about 35 ° C. after stirring. Next, about 8 hours later, the second stirring (middle process) was performed to cool the heat. Again, the product temperature was controlled to around 35 ° C. with ventilation, and after about 16 hours, the third stirring (closing process) was performed in the same manner as the previous time. Thereafter, the temperature was controlled while ventilating so that the product temperature was about 38 ° C., and the ironmaking was finished 48 hours after the start. After completion of the koji making, the water content is adjusted while stirring so that the water content becomes 50%, and the product is heated so that the product temperature becomes about 50 ° C., and then the isoflavone compound in the defatted soybean with the koji mold enzyme for 48 hours or more. It hydrolyzed until most of it became an aglycon body. As shown in Table 1, a large amount of defatted soybean isoflavone compound was obtained by treatment according to the present invention so that aglycone daidzein was the main component.
この製麹に用いる麹菌としては、古くからの日本独特の発酵食品やテンペに用いられている麹菌であり、食品として安全なアスペルギルス・ウサミ、アスペルギルス・カワチ、アスペルギルス・アワモリ、アスペルギルス・サイトイ、アスペルギルス・オリゼー、アスペルギルス・ニガー等アスペルギルス属およびリゾープス属等からなる麹菌を用いるとよい。 As the koji mold used in this koji making, it is koji mold that has been used in traditional Japanese fermented foods and tempeh. Aspergillus oryzae or Aspergillus niger or other Aspergillus genus, Rhizopus genus or the like may be used.
この発酵時間については、使用する麹菌の種類に応じて、少なくとも２４時間以上であり、脱脂大豆中のイソフラボン化合物の配糖体を十分に分解させるに十分な発酵時間とするとよい。 The fermentation time is at least 24 hours or longer depending on the type of koji mold used, and is preferably set to a fermentation time sufficient to sufficiently decompose the glycoside of the isoflavone compound in the defatted soybean.
この蛋白質の加水分解については、使用する麹菌の種類に応じて、脱脂大豆中のイソフラボン化合物の配糖体を十分に低減させるに十分な加水分解時間ならびに加水分解温度とするとよい。 About hydrolysis of this protein, it is good to set it as hydrolysis time and hydrolysis temperature sufficient to fully reduce the glycoside of the isoflavone compound in defatted soybean according to the kind of koji mold used.
このようにすれば、発酵の初期において有機酸を生成して脱脂大豆中の雑菌の増殖を抑制し、２次汚染の心配がなくなり、脱脂大豆を原料とした固形生成物を大量生産することができる。また、低水分としなくともイソフラボン化合物の配糖体を十分に低減させる処理を施すことができる。 In this way, it is possible to produce organic acids at the initial stage of fermentation to suppress the growth of germs in the defatted soybean, eliminate the risk of secondary contamination, and mass-produce solid products made from defatted soybean. it can. Moreover, even if it does not set it as low moisture, the process which fully reduces the glycoside of an isoflavone compound can be given.
加水分解の終了後には、組成物を乾燥させ、必要に応じて粉砕することにより花粉症改善用素剤を得る。 After completion of the hydrolysis, the composition is dried and pulverized as necessary to obtain a hay fever remedy.
更に、この固形生成物である花粉症改善用素剤には前記の一連の生産工程を経ることにより乳酸菌が増殖されていることがわかった。 Furthermore, it was found that lactic acid bacteria were propagated through the above-described series of production steps in the hay fever remedy, which is a solid product.
その乳酸菌の種類を各種の検出培地を用いて増殖させて検出したところ、乳酸菌はペディオコッカス属（Pediococcus sp.）とエントロコッカス属（Entrococcus sp.）とを含み、当該ペディオコッカス属およびエントロコッカス属の菌数の比が約３：１であることが判明した。 When the type of the lactic acid bacterium was grown and detected using various detection media, the lactic acid bacterium contained Pediococcus sp. And Entrococcus sp. It was found that the ratio of the number of Coccus bacteria was about 3: 1.
また、更に本実施形態の花粉症改善用素剤には、麹菌および乳酸菌が増殖することによる固形組成物の代謝成分として、例えば、多糖類、ペプチド等が産生されていることがわかった。 In addition, it was found that, for example, polysaccharides, peptides, and the like are produced as metabolic components of the solid composition resulting from the growth of gonococci and lactic acid bacteria in the hay fever amelioration base of this embodiment.
本発明者は、このようにして形成されている本発明の花粉症改善用素剤には、これまでに発見されていないペディオコッカス属の乳酸菌がリッチに含有されていることに着目して、当該固形生成物を花粉症を患っている被検者に投与したところ、花粉症が大きく回復された。また、本発明の花粉症改善用素剤に含まれる麹菌や乳酸菌は生菌および死菌を問わずに花粉症が大きく回復された。 The inventor of the present invention pays attention to the fact that the hay fever remedy of the genus Pediococcus that has not been discovered so far is contained in the hay fever ameliorating base of the present invention thus formed. When the solid product was administered to a subject suffering from hay fever, hay fever was greatly recovered. In addition, gonococci and lactic acid bacteria contained in the hay fever remedy of the present invention were greatly recovered in hay fever regardless of viable or dead bacteria.
更に、本発明の花粉症改善用素剤には麹菌や乳酸菌のほかに麹菌および乳酸菌が増殖することによる固形組成物の代謝成分が含まれているので、単なる乳酸菌を成分とする組成物に比較して花粉症の回復される効果が高いものであることが確認された。 Furthermore, since the base for hay fever improvement of the present invention contains a metabolic component of a solid composition resulting from the growth of gonococci and lactic acid bacteria in addition to gonococci and lactic acid bacteria, it is compared with a composition containing mere lactic acid bacteria as a component. Thus, it was confirmed that the effect of recovering hay fever was high.
実施例１（乳酸菌の検出）
原料として脱脂大豆を用い、麹菌としてアスペルギルス・オリゼーを用いて前記の生産工程に従って本発明の花粉症改善用素剤を春夏秋冬の各季節において生産して製品春、製品夏、製品秋、製品冬とした。これらの製品に対して下記の各種培地を用いて、それぞれの培地の性質に応じて増殖することのできる菌を培養してその菌数を求めた。
＜培地と増殖適応菌種＞
１ Trypticase Soy Blood Agar (base BBL) → 好気性菌
２ Trypticase Soy Agar (BBL) → 好気性菌
３ DHL寒天培地（栄研） → 大腸菌群
４ TATAC寒天培地 → 乳酸菌(エントロコッカス属)
５ ポテトデキストロース寒天培地(栄研) → 酵母
６ 変法LBS寒天培地 (base BBL) → 乳酸菌(ペディオコッカス属)
＜菌叢の検索方法＞
各製品の試料１ｇを秤量し、直ちに９ｍｌの希釈液を含む中試験管に移しよく混和（１０−１）させた。その１ｍｌに新しい希釈液９ｍｌを加え、同様に１０−８倍まで希釈し、順次希釈液の０．０５ｍｌを前記の６種の寒天平板に一様に塗抹した。
培地１〜３は３７℃で２４時間、培地４は３７℃で４８時間、培地５は３０℃で７２時間の条件でそれぞれ好気培養した。培地６は、ジャーに入れ、還元スチールウールを入れずに、容器内を炭酸ガスで１回置換して３７℃で４８時間の条件で微好気培養、あるいは３０℃で４８時間の条件で好気培養した。
＜生菌数の測定結果＞
培養終了後、６種の各培地に発育した集落の形状およびその数を記録し、それぞれグラム染色を行なった。集落の形状、グラム染色、菌の形態および発育温度その他によって菌群を決定して集計した。その結果は表２の通りである。
この表２に示す結果より、各製品に含まれる生菌の大部分は、乳酸菌であり、その乳酸菌はペディオコッカス属とエントロコッカス属とを含み、当該ペディオコッカス属およびエントロコッカス属の菌数の比が約３：１であることがわかった。
Example 1 (Detection of lactic acid bacteria)
Using the defatted soybeans as raw materials and Aspergillus oryzae as the koji molds, the hay fever improving ingredients of the present invention are produced in each season of spring, summer, autumn and winter according to the above production process, and products spring, product summer, product fall, product It was winter. The following various culture media were used for these products, and bacteria that could grow according to the properties of each culture medium were cultured to determine the number of bacteria.
<Medium and growth-adapted bacterial species>
1 Trypticase Soy Blood Agar (base BBL) → Aerobic bacteria 2 Trypticase Soy Agar (BBL) → Aerobic bacteria 3 DHL agar medium (Eiken) → E. coli group 4 TATAC agar medium → Lactic acid bacteria (genus Entrococcus)
5 Potato dextrose agar medium (Eiken) → Yeast 6 Modified LBS agar medium (base BBL) → Lactic acid bacteria (Pediococcus spp.)
<Search method for bacterial flora>
A 1 g sample of each product was weighed and immediately transferred to a medium test tube containing 9 ml of diluent and mixed well (10 −1 ). 9 ml of a new diluted solution was added to 1 ml of the diluted solution, and the solution was similarly diluted to 10-8 times, and 0.05 ml of the diluted solution was spread on the above-mentioned six kinds of agar plates uniformly.
Media 1 to 3 were subjected to aerobic culture at 37 ° C. for 24 hours, Medium 4 at 37 ° C. for 48 hours, and Medium 5 at 30 ° C. for 72 hours. Medium 6 is placed in a jar, without reducing steel wool, and the inside of the container is replaced once with carbon dioxide gas. The culture medium is microaerobically cultured at 37 ° C. for 48 hours, or preferably at 30 ° C. for 48 hours. Air-cultured.
<Measurement result of viable count>
After completion of the culture, the shape and number of colonies grown on each of the six types of media were recorded, and Gram staining was performed. The fungus group was determined and aggregated according to the shape of the colony, Gram stain, fungus morphology and growth temperature, and others. The results are shown in Table 2.
From the results shown in Table 2, most of the viable bacteria contained in each product are lactic acid bacteria, and the lactic acid bacteria include genus Pediococcus and Entrococcus, and the bacteria belonging to the genus Pediococcus and Entrococcus. The number ratio was found to be about 3: 1.
実施例２
次に、本発明の穀物由来の花粉症改善用素剤による花粉症の改善、治療作用を説明する。
被験者として４１名（男女比が４８．８％：５１．２％、平均年齢が４３．７歳）に対して、昨年春期に２箇月間に亘って前記製品１を１日当り７５０ｍｇ〜３．０ｇを摂取することにより花粉症の改善、治療作用を検証した。
＜被験者の試験開始時の花粉症歴＞
被験者の試験開始時における花粉症歴は、１年未満が４．９％、３年未満が４．９％、５年未満が１７．１％、１０年未満が２４．４％、１０年以上が４８．８％であった。
＜被験者の試験開始時の花粉症の症状＞
被験者の試験開始時における花粉症の症状は、軽症が１２．２％、中等症が４６．３％、重症が３１．７％、最重症が９．８％であった。ここで、軽症とは、くしゃみが１日５回程度出る、鼻水が１日５回程度出る、目がかゆい等の症状が発症している状態であり、中等症とは、軽症の症状の程度が悪化する他に鼻づまり、目の充血等の症状が発症している状態であり、重症とは、軽症および中等症の症状の悪化、即ちくしゃみが止まらない、鼻水が止まらない、鼻づまりがひどく口で息をする必要がある等他に涙が必要以上にでる、目やにが出る、目が腫れぼったい、鼻のかゆみ、頭痛、微熱、咳が出る、皮膚のかゆみ、蕁麻疹が出る、耳のかゆみ、喉のかゆみ、喉の痛み等の症状が発症している状態をいう。
＜被験者の花粉症の改善度合い＞
被験者の試験終了後における一昨年度と比較した花粉症の改善度合いは、被験者の花粉症に対する全体的な症状で判断した結果において、非常に有効が１４．６％、有効が４８．８％、普通に有効が１９．５％、無効が１２．２％、わからないが４．９％となり、普通に有効以上の効果を認めた被験者が８２．９％であり、花粉症が大きく改善されたことがわかる。特に、昨年春期の花粉の飛散量は一昨年度の５０〜１００倍にも達するものであり、花粉症が改善されたとする本試験の結果は、本発明品を摂取しないならば花粉症が重症になる可能性が高かったものが、花粉症の症状が改善されたこととなるので、その改善度合いは非常に大きいものであるということができる。
花粉症の具体的症状について、それぞれを一昨年度と比較して、改善ポイントを悪化したを０点、不変を１点、やや緩和したを２点、緩和したを３点、完治したを４点として集計すると表３の通りとなった。
Next, the improvement and therapeutic action of hay fever by the grain-derived hay fever improvement ingredient of the present invention will be described.
For 41 subjects (male ratio 48.8%: 51.2%, average age 43.7 years), 750mg to 3.0g of product 1 per day for 2 months in the spring of last year The effect of hay fever improvement and treatment was verified.
<History of hay fever at the start of the test>
The hay fever history at the start of the study was 4.9% for less than 1 year, 4.9% for less than 3 years, 17.1% for less than 5 years, 24.4% for less than 10 years, 10 years or more Was 48.8%.
<Symptoms of hay fever at the start of the test>
The symptoms of hay fever at the start of the study were 12.2% for mild, 46.3% for moderate, 31.7% for severe, and 9.8% for most severe. Here, mild is a condition in which symptoms such as sneezing about 5 times a day, runny nose occurs about 5 times a day, itchy eyes, etc. Moderate is the degree of mild symptoms In addition to worsening of symptoms, symptoms such as nasal congestion and redness of the eyes have developed, and severe refers to worsening of mild and moderate symptoms, ie, sneezing does not stop, runny nose does not stop, nasal congestion is severe Necessary to breathe in the mouth, etc.More tears than necessary, eyes and rashes, swollen eyes, itchy nose, headache, slight fever, cough, itchy skin, urticaria, ear This refers to a condition in which symptoms such as itching of the throat, itching of the throat, and sore throat have developed.
<Degree of improvement in hay fever in subjects>
The degree of improvement in hay fever compared to the previous year after the end of the test was 14.6% very effective and 48.8% effective according to the overall symptom of the subject's hay fever. Effectiveness was 19.5%, invalidity was 12.2%, unknown but 4.9%, and 82.9% of the subjects were more effective than normal, and hay fever was greatly improved. Recognize. In particular, the amount of pollen scattered last spring was 50 to 100 times that of the previous year, and the results of this study that hay fever was improved showed that hay fever would be serious if the product of the present invention was not taken. Since the symptom of hay fever has been improved, the degree of improvement can be said to be very high.
Regarding specific symptoms of hay fever, each point was compared with the previous year, 0 points for improvement, 1 point for unchanged, 2 points for moderate relief, 3 points for relief, 4 points for complete cure The results are shown in Table 3.
なお、本発明は、前述した実施の形態並びに実施例に限定されるものではなく、必要に応じて種々の変更が可能である。 The present invention is not limited to the above-described embodiments and examples, and various modifications can be made as necessary.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006127542A JP5624706B2 (en) | 2006-05-01 | 2006-05-01 | Pollen allergy remedy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006127542A JP5624706B2 (en) | 2006-05-01 | 2006-05-01 | Pollen allergy remedy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007297344A true JP2007297344A (en) | 2007-11-15 |
| JP5624706B2 JP5624706B2 (en) | 2014-11-12 |
Family
ID=38767152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006127542A Active JP5624706B2 (en) | 2006-05-01 | 2006-05-01 | Pollen allergy remedy |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5624706B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020000033A (en) * | 2018-06-26 | 2020-01-09 | 国立大学法人広島大学 | Oral immune tolerance inducing agent, food and medicament containing the same, and process for producing processed food |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000045830A1 (en) * | 1999-02-04 | 2000-08-10 | Nichimo Co., Ltd. | Materials for preventing arteriosclerosis, immunopotentiating materials, vertebrates fed with these materials and eggs thereof |
| JP2003113114A (en) * | 2001-10-09 | 2003-04-18 | Nichimo Co Ltd | Immunostimulator |
| JP2006067881A (en) * | 2004-09-01 | 2006-03-16 | Nichimo Co Ltd | New lactic acid bacterium and lactic acid bacterium preparation |
| JP2006104107A (en) * | 2004-10-04 | 2006-04-20 | Nichimo Co Ltd | Anti-food allergic agent |
-
2006
- 2006-05-01 JP JP2006127542A patent/JP5624706B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000045830A1 (en) * | 1999-02-04 | 2000-08-10 | Nichimo Co., Ltd. | Materials for preventing arteriosclerosis, immunopotentiating materials, vertebrates fed with these materials and eggs thereof |
| JP2003113114A (en) * | 2001-10-09 | 2003-04-18 | Nichimo Co Ltd | Immunostimulator |
| JP2006067881A (en) * | 2004-09-01 | 2006-03-16 | Nichimo Co Ltd | New lactic acid bacterium and lactic acid bacterium preparation |
| JP2006104107A (en) * | 2004-10-04 | 2006-04-20 | Nichimo Co Ltd | Anti-food allergic agent |
Non-Patent Citations (8)
| Title |
|---|
| JPN6012007643; 週刊医学のあゆみ， Ｖｏｌ．２０７ Ｎｏ．１０ （２００３） ｐ．８１１-８１４ * |
| JPN6012007648; Ｊ Ａｐｐｌ Ｍｉｃｒｏｂｉｏｌ．， １００［４］ （２００６ Ａｐｒ） ｐ．８１３-２０． * |
| JPN6012066014; Ｊ Ａｌｌｅｒｇｙ Ｃｌｉｎ Ｉｍｍｕｎｏｌ．， Ｖｏｌ．１１７ Ｉｓｓｕｅ ２（Ｓｕｐｐｌ） ｐ．Ｓ３２７（１２６３） Ｆｅｂ ２００６ |
| JPN6012066017; Ｊ Ａｇｒｉｃ Ｆｏｏｄ Ｃｈｅｍ．， Ｖｏｌ．４８， （２０００） ｐ．１３６７-１３７２ |
| JPN6012066018; 医学のあゆみ， Ｖｏｌ．１９６ Ｎｏ．２， （２００１） ｐ．１６９-１７０ |
| JPN6012066020; Ｖａｃｃｉｎｅ， Ｖｏ．２２ （２００３） ｐ．８７-９５ |
| JPN6012066022; 機能性食品と薬理栄養， Ｖｏｌ．３ Ｎｏ．２， （２００５） ｐ．７９-８４ |
| JPN6012066023; 月刊アレルギーの臨床， Ｖｏｌ．３４２， （Ｆｅｂ ２００６） ｐ．１４０-１４４ |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020000033A (en) * | 2018-06-26 | 2020-01-09 | 国立大学法人広島大学 | Oral immune tolerance inducing agent, food and medicament containing the same, and process for producing processed food |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5624706B2 (en) | 2014-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104818229B (en) | A kind of steamed bun leavening and its preparation method and application | |
| CN103070285B (en) | Microbe feed additive and preparation method thereof | |
| CN106974063A (en) | It is a kind of that the method that bacillus coagulans produces High efficiency protein feed is cooperateed with feeding enzyme | |
| CN107574136A (en) | A kind of preparation method of semi-solid probiotics used for aquiculture | |
| JPWO2007058061A1 (en) | Brewing seed meal, brewing meal, brewed food, and production method thereof | |
| KR102000475B1 (en) | Bacillus amyloliquefaciens NY12-2 strain having antibiotic activity against Bacillus cereus and inhibitory activity on biogenic amine and compositions thereof | |
| CN109770060A (en) | A method of preparing soybean stalk feed | |
| CN110074325A (en) | The method that pure culture fermentation combines semidry method milling to prepare rice flour | |
| CN109157547A (en) | For treating the lactic acid bacteria composite fungicide of depression | |
| CN114806975A (en) | Microecological preparation containing enterogenous probiotics as well as preparation method and application of microecological preparation | |
| JP5624706B2 (en) | Pollen allergy remedy | |
| KR101424167B1 (en) | The fermentation method for mixed grains using novel lactic acid bacteria isolated from grains and its production methods | |
| CN111296848A (en) | Edible bacillus coagulans powder and preparation process thereof | |
| JP2019517810A (en) | Bacillus licheniformis NY1505 strain producing a large amount of α-glucosidase inhibitor | |
| CN102618429A (en) | Chrysanthemum vinegar capable of regulating blood fat and lowering blood pressure and preparation process thereof | |
| CN103829040A (en) | Method for compounding and fermenting soybean meal by Chenxiang tea and bacillus subtilis and application | |
| KR20030075996A (en) | Feed additives using Bacillus subtilis and Saccharomyces cerevisiae, and a method of manufacture thereof | |
| JP2014205634A (en) | External preparation for skin | |
| CN106962643A (en) | A kind of production method of nonreactive grower pigs fermented feed | |
| KR102166789B1 (en) | Mutant lactic acid bacterium strain having acid and heat resistance, and culturing composition comprising this strain as effective gredient | |
| KR101236309B1 (en) | Medium composition for high concentration culture of Bacillus and uses thereof | |
| CN106929386A (en) | The method that flat mushroom pre fermentation coarse cereals prepare smoked vinegar | |
| JP2009114095A (en) | Raw preparation for ameliorating allergic symptom | |
| KR20140133249A (en) | A manufacturing method to improve flavor-taste and stability of rice wine | |
| KR102260320B1 (en) | Synbiotic composition comprising lactulose and probiotic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090408 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120416 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120717 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121017 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20121031 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20121221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140825 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140929 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5624706 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |